Cerca
Menu
Foto del docente

Margherita Nannini

Senior assistant professor (fixed-term)

Department of Medical and Surgical Sciences

Academic discipline: MED/06 Medical Oncology

Curriculum vitae

Date of birth: May 17, 1982

Position

From March 2022: Senior assistant professor at Department of Experimental, Diagnostic and Specialty Medicine - DIMES - Academic discipline: MED/06 Medical Oncology

From March 2020 to March 2022: Medical Oncologist (Medical Oncology Unit - IRCCS University Hospital of Bologna, Via Albertoni 15, 40138 Bologna)

From 1/AUG/2014 to 31/07/2019: Researcher at Department of Specialized, Experimental and Diagnostic Medicine of the University of Bologna – Istituto L.A. Seragnoli, Policlinico S.Orsola-Malpighi, via Massarenti 9, 40138, Bologna. Project title: “Biology and treatment of rare tumors on a molecular basis as a clinical model in medical oncology”

From April 2017: National Scientific Qualification for associated professor.

Education and training:

  • 14/07/2001: Graduation at the High School, Liceo Classico “L. Galvani”, Bologna (vote: 100/100).
  • 11/06/2007: Degree in Medicine and Surgery, University of Bologna. Thesis Title: “Study of gene expression profiling of colorectal liver metastases”. Result: 110/100 cum laude
  • 2008 March – October 2012: Specialization training program in Medical Oncology at Department of Hematology and Oncological Sciences “L.A. Seragnoli”, S.Orsola-Malpighi Hospital, University of Bologna
  • 30 October 2012: Specialization in Medical Oncology at Department of Hematology and Oncological Sciences “L.A. Seragnoli”, S.Orsola-Malpighi Hospital, University of Bologna. Thesis title: “Genomic Analysis of KIT/PDGFRA Wild-type (WT) gastrointestinal stromal tumors (GIST) with next generation sequencing approach”. Vote: 70/70 cum laude
 

Membership

  • Member of ERN-EURACAN (IRCCS Azienda Ospedaliero-Universitaria di Bologna)
  • Membrer of GISTSTUDYGROUP of Bologna (www.giststudygroup.it)
  • Member of SARCOMASTUDYGROUP of Bologna (www.sarcomastudygroup.it)
  • Referent of WT GIST Unit of Bologna
  • Member of multidisciplinary team of GIST/SOFT TISSUE SARCOMAS P
  • Member of multidisciplinary team GROT (Gruppo di Oncologia Tiroidea)
  • Member of multidisciplinary team of adrenal diseases

Award

  • May 14 to 15, 2013 (Prague): award for the best case study presented at ARCHEOLOGIST Summit 2013.

Lectures

    • GIST E TUMORI RARI: PERCORSO DIAGNOSTICO-TERAPEUTICO NELLA PRATICA CLINICA (Palermo, 3-4 Aprile 2012): Highlights: GIST le mutazioni oltre c-kit e PDGFRA
    • GASTRO IN 2012 (Firenze, 24-25 Settembre 2012): Tumori Stromali Gastrointestinali (GIST)
    • ARCHEOLOGIST Summit 2013 (Prague, 14-15 Maggio 2013): Tailoring therapy with sunitinib in a elderly patient with advanced GIST
    • XVIII RIUNIONE ANNUALE ITALIAN SARCOMA GROUP (Padova, 7-8 Aprile 2014): Novità nel 2014: analisi mutazionale di KIT/PDGFRA sul sangue periferico
    • GIST, dalle evidenze scientifiche alla pratica clinica (Bologna, 11 Aprile 2014): PDTA GIST e sarcomi addominali: un’esperienza da esportare
    • XIX RIUNIONE ANNUALE ITALIAN SARCOMA GROUP (Firenze, 10-11 Aprile 2015): GIST: novità in tema di biologia molecolare
    • 1° Congresso Nazionale IART (Cremona 7 e 8 maggio 2015): GIST: Basi molecolari della terapia a bersaglio molecolare
    • GIST, PERCORSO DIAGNOSTICO-TERAPEUTICO NELLA PRATICA CLINICA (Bologna, 17 MARZO 2016): Terapia medica e trattamenti loco-regionali nei GIST: un approccio integrato
    • Il POLICLINICO S.ORSOLA-MAPIGHI IN EUROPA RIFERIMENTO PER I TUMORI RARI (Bologna, 27 SETTEMBRE 2017): L'importanza dei centri di riferimento nei GIST
    • UPDATE NELLA DIAGNOSTICA E TERAPIA DELLE PATOLOGIE TIROIDEE E PARATIROIDEE (Bologna, 17-18 GENNAIO 2019): Nuovi scenari di Terapia Medica nei Carcinomi Differenziati della tiroide
    • XXIII RIUNIONE ANNUALE ITALIAN SARCOMA GROUP (Pisa, 4-6 Aprile 2019): GIST: journal club
    • FORTRESS20 (Essen, 23-24 Gennaio 2020): D842V: the code of resistance
    • WEBINAR A.I.G (29/04/2021): GIST Wild Type Unit Bologna
    • GIST E SARCOMI VISCERALI: RETE REGIONE EMILIA-ROMAGNA (26/05/2021): L’esempio della GIST WT Unit
    • FAD SINCRONA WEBINAR - Corso ECM GIST: MARKERS TISSUTALI E ONCOLOGIA DI PRECISIONE (13 Maggio 2021): moderatore nella sessione TRATTAMENTO MEDICO DEL PAZIENTE AFFETTO DA GIST
    • WEBINAR A.I.G (08/07/2021): I GIST: La doppia faccia della mutazione D842V
    • TUMORE TIROIDEO IN STADIO AVANZATO NELL’ERA DELLA MEDICINA DI PRECISIONE (24 Settembre 2021): Caso clinico: quando e come trattare con i nuovi farmaci
    • TEST MOLECOLARI MULTIGENICI E TERAPIE AGNOSTICHE: LUCI E OMBRE (18/11/2021): Quando chiedere un’analisi molecolare multigenica

Clinical trials:


Principal Investigator according to Good Clinical Practice in:

    1. METROPHOLYS: Ciclofosfamide metronomica vs Doxorubicina in pazienti anziani con sarcoma dei tessuti molli in stadio avanzatoStudio clinico controllato, randomizzato, in aperto
    1. Protocollo ad uso terapeutico nominale di Larotrectinib nei pazienti con carcinoma della tiroide iodio-refrattario con riarrangiamento di NTRK
    2. Protocollo ad uso terapeutico nominale di Trametinib nei pazienti con GIST metastatico NF1-relato resistente
    3. ARTICLE: Studio randomizzato di fase II sull’attività della Trabectedina vs Gemcitabina in pazienti con leiomiosarcoma metastatico o localmente avanzato pretrattati con chemioterapia convenzionale
       

    Sub-Investigator, Co-Investigator according to Good Clinical Practice in:

    • ISG-TOMAS2: Studio di fase 2 randomizzato sulla combinazione di trabectedin + olaparib vs. trabectedin in pazienti affetti da sarcoma non operabile avanzato o metastatico dopo il fallimento delle linee di trattamento standard
    • DCC-2618-03-002: A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
    • BLU-285-1303: “Studio internazionale di fase 3, multicentrico, in aperto, randomizzato per valutare BLU-285 rispetto a regorafenib in pazienti con tumore stromale gastrointestinale (GIST) non resecabile o metastatico localmente avanzato”
    • CrenoGIST: A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene
    • Novartis CSTI571X2103: A dose-finding phase Ib multicenter study of imatinib in combination with the oral phosphatidyl-inositol 3- kinase (PI3K) inhibitor BYL719 in patients with gastrointestinal stromal tumor (GIST) who failed prior therapy with imatinib and sunitinib
    • TROBS: Trabectedin in soft tissue sarcoma. A retrospective observational analysis.
    • ALDOXORUBIN-P3-STS-01: Studio multicentrico, randomizzato, in aperto, di Fase 3 per valutare l’efficacia e la sicurezza di aldoxorubicina rispetto alla scelta dello sperimentatore in soggetti con sarcomi dei tessuti molli metastatici, localmente avanzati o non resecabili, recidivati o refrattari dopo trattamento chemioterapico non adiuvante
    • BAY 73-4506/14874: “Studio randomizzato, in doppio cieco, controllato verso placebo, di fase III su regorafenib più la migliore terapia di supporto verso placebo più la migliore terapia di supporto in soggetti con tumori stromali gastrointestinali metastatici e/o non resecabili (GIST) la cui malattia è progredita nonostante un trattamento precedente con almeno imatinib e sunitinib”
    • Protocollo ad uso terapeutico nominale di Olaratumab nei pazienti con sarcoma avanzato
    • Protocollo ad uso terapeutico nominale di Ripretinib nei pazienti con GIST resistenti
    • Protocollo ad uso terapeutico nominale di Avapritinib nei pazienti con GIST resistenti e GIST D842V

Research field:
Main research fields:

  • Gastrointestinal tumors
  • Soft Tissue Sarcomas
  • Thyroid cancer

Peer-reviewed publications

  1. 2022

    1. Ravegnini G, Fosso B, Ricci R, Gorini F, Turroni S, Serrano C, Pilco-Janeta DF, Zhang Q, Zanotti F, De Robertis M, Nannini M, Pantaleo MA, Hrelia P, Angelini S. Analysis of microbiome in gastrointestinal stromal tumors: Looking for different players in tumorigenesis and novel therapeutic options. Cancer Sci. 2022 May 28. doi: 10.1111/cas.15441. Epub ahead of print. PMID: 35633186.
    2. Pantaleo MA, Urbini M, Schipani A, Nannini M, Indio V, De Leo A, Vincenzi B, Brunello A, Grignani G, Casagrande M, Fumagalli E, Conca E, Saponara M, Gruppioni E, Altimari A, De Biase D, Tallini G, Ravegnini G, Turchetti D, Seri M, Ardizzoni A, Secchiero P, Astolfi A. SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. Front Oncol. 2022 Jan 4;11:778461.

    2021

    1. Dondi G, Porcu E, De Palma A, Damiano G, De Crescenzo E, Cipriani L, Dirodi M, Ravegnini G, De Leo A, Nannini M, Ferioli M, Morganti AG, Pantaleo MA, De Iaco P, Perrone AM. Uterine Preservation Treatments in Sarcomas: Oncological Problems and Reproductive Results: A Systematic Review. Cancers (Basel). 2021 Nov 19;13(22):5808.
    2. Ravegnini G, Ferioli M, Morganti AG, Strigari L, Pantaleo MA, Nannini M, De Leo A, De Crescenzo E, Coe M, De Palma A, De Iaco P, Rizzo S, Perrone AM. Radiomics and Artificial Intelligence in Uterine Sarcomas: A Systematic Review. J Pers Med. 2021 Nov 11;11(11):1179.
    3. Vincenzi B, Napolitano A, Fiocco M, Mir O, Rutkowski P, Blay JY, Reichardt P, Joensuu H, Fumagalli E, Gennatas S, Hindi N, Nannini M, Spalato Ceruso M, Italiano A, Grignani G, Brunello A, Gasperoni S, De Pas T, Badalamenti G, Pantaleo MA, van Houdt WJ, IJzerman NS, Steeghs N, Gelderblom H, Desar IME, Falkenhorst J, Silletta M, Sbaraglia M, Tonini G, Martin-Broto J, Hohenberger P, Le Cesne A, Jones RL, Dei Tos AP, Gronchi A, Bauer S, Casali PG. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clin Cancer Res. 2021 Oct 6.
    4. Nannini M, Rizzo A, Nigro MC, et al. Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study. ESMO Open. 2021 Aug;6(4):100222.
    5. Nannini M, Rizzo A, Indio V, Schipani A, Astolfi A, Pantaleo MA. Targeted therapy in SDH-deficient GIST. Ther Adv Med Oncol. 2021 Jun 28;13:17588359211023278.
    6. Indio V, Schipani A, Nannini M, Urbini M, Rizzo A, De Leo A, Altimari A, Di Scioscio V, Messelodi D, Tarantino G, Astolfi A, Pantaleo MA. Gene Expression Landscape of SDH-Deficient Gastrointestinal Stromal Tumors. J Clin Med. 2021 Mar 4;10(5):1057.
    7. Rizzo A, Pantaleo MA, Astolfi A, Indio V, Nannini M. The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST). Cancers (Basel). 2021;13(4):705.
    8. Pantaleo MA, Mandruzzato M, Indio V, Urbini M, Nannini M, Gatto L, Schipani A, Fiorentino M, Franceschini T, Ambrosini V, Di Scioscio V, Saponara M, Ianni M, Concetti S, Altimari A, Ardizzoni A, Astolfi A. Case Report: The Complete Remission of a Mixed Germ Cell Tumor With Somatic Type Malignancy of Sarcoma Type With a GCT-Oriented Therapy: Clinical Findings and Genomic Profiling. Front Oncol. 2021 Mar 16;11:633543.

    2020

    1. Rizzo A, Nigro MC, Ramponi V, Gallo C, Perrone AM, De Iaco P, Frezza G, Balestrini D, Di Benedetto M, Morbiducci J, Pantaleo MA, Nannini M. Skull Metastasis From Uterine Leiomyosarcoma, a Rare Presentation for a Rare Tumor: A Case Report and Review of the Literature. Front Oncol. 2020 Jun 16;10:869.
    2. Paolisso P, Saturi G, Foà A, Saponara M, Nannini M, Pantaleo MA, Leone O, Turchetti D, Calistri D, Savini C, Pacini D, Pizzi C, Galiè N. Primary malignant pericardial tumour in Lynch syndrome. BMC Cancer. 2020 Mar 6;20(1):191.
    3. Astolfi A, Nannini M, Indio V, Schipani A, Rizzo A, Perrone AM, De Iaco P, Pirini MG, De Leo A, Urbini M, Secchiero P, Pantaleo MA. Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. Cancers (Basel). 2020 Jul 31;12(8):2126.
    4. Rizzo, A., Nannini, M., Astolfi, A., Indio, V., De Iaco, P., Perrone, A. M., De Leo, A., Incorvaia, L., Di Scioscio, V., & Pantaleo, M. A. Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis. Cancers 2020; 12:1899.
    5. Indio V, Ravegnini G, Astolfi A, Urbini M, Saponara M, De Leo A, Gruppioni E, Tarantino G, Angelini S, Pession A, Pantaleo MA, Nannini M. Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation. Front Immunol. 2020;11:851.
    6. Nannini M, Valerio DS, Gruppioni E, Altimari A, Chiusole B, Saponara M, Pantaleo MA, Brunello A. Complete radiological response to first-line regorafenib in a patient with abdominal relapse of BRAF V600E mutated GIST. Therap Adv Gastroenterol. 2020;13:1756284820927305.
    7. Astolfi A, Pantaleo MA, Indio V, Urbini M, Nannini M. The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor. Int J Mol Sci. 2020;21:3313.
    8. Urbini M, Astolfi A, Indio V, Nannini M, Pizzi C, Paolisso P, Tarantino G, Pantaleo MA, Saponara M. Genetic aberrations and molecular biology of cardiac sarcoma. Ther Adv Med Oncol. 2020;12:1758835920918492.
    9. Astolfi A, Indio V, Nannini M, Saponara M, Schipani A, De Leo A, Altimari A, Vincenzi B, Comandini D, Grignani G, Secchiero P, Urbini M, Pantaleo MA. Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST. Front Oncol. 2020;10:504.
    10. Gatto L, Del Gaudio M, Ravaioli M, Cescon M, Tonini V, Cervellera M, Franceschelli A, Pirini MG, Di Scioscio V, Buia F, Niro F, Capizzi E, Fiorentino M, Astolfi A, Indio V, Nannini M, Pantaleo MA, Saponara M. Paratesticular Mesenchymal Malignancies: A Single-Center Case Series, Clinical Management, and Review of Literature. Integr Cancer Ther 2020 Jan;19:1534735419900554.
    11. Napolitano A, Provenzano S, Colombo C, Vitellaro M, Brunello A, Badalamenti G, Nannini M, Ibrahim T, Hohenberger P, Gasperoni S, Gennatas S, Jones RL, Hindi N, Martin-Broto J, Spalato Ceruso M, Silletta M, Dei Tos AP, Gronchi A, Stacchiotti S, Santini D, Tonini G, Palassini E, Vincenzi B. Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. ESMO Open. 2020;5:e000604.

    2019

    1. Rizzo A, Serban ED, Ricci AD, Nannini M, Saponara M, Cancellieri A, Paioli D, Trisolini R, Pantaleo MA. Granular cell tumor of the trachea as a rare cause of dyspnea in a young woman. Respir Med Case Rep. 2019 Oct 25;28:100961.
    2. Saponara M, Indio V, Pizzi C, Serban ED, Urbini M, Astolfi A, Paolisso P, Suarez SM, Nannini M, Pacini D, Agostini V, Leone O, Ambrosini V, Tarantino G, Fanti S, Niro F, Buia F, Attinà D, Pantaleo MA. Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report. World J Clin Cases. 2019 Oct 6;7(19):3018-3026.
    3. Pantaleo MA, Tarantino G, Agostinelli C, Urbini M, Nannini M, Saponara M, Castelli C, Stacchiotti S, Fumagalli E, Gatto L, Santini D, De Leo A, Marafioti T, Akarca A, Sabattini E, Pession A, Ardizzoni A, Indio V, Astolfi A. Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. Oncoimmunology. 2019 Jun 4;8(9):e1617588
    4. Rizzo A, Pantaleo MA, Saponara M, Nannini M. Current status of the adjuvant therapy in uterine sarcoma: A literature review. World J Clin Cases. 2019 Jul 26;7(14):1753-1763.
    5. Ravegnini G, Serrano C, Simeon V, Sammarini G, Nannini M, Roversi E, et al. The rs17084733 variant in the KIT 3' UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility. Epigenetics. 2019 Jun;14(6):545-557
    6. Urbini M, Indio V, Tarantino G, Ravegnini G, Angelini S, Nannini M, Saponara M, et al.. Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST. Genes Chromosomes Cancer. 2019 [Epub ahead of print]
    7. Nannini M, Tarantino G, Indio V, et al. Molecular modeling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib. Scientific Reports 2019;9(1):2172.

    2018

    1. Saponara M, Ambrosini V, Nannini M, Gatto L, Astolfi A, Urbini M, Indio V, Fanti S, Pantaleo MA. (18)F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. Ther Adv Med Oncol. 2018;10:1758835918793569.
    2. Ardizzoni A, Nannini M, Morganti A.G. Metastasi cerebrali e meningosi - Manuale di oncologia medica COMU Collegio degli Oncologi Medici Italiani I edizione (2018) ISBN: 978-88-7711-939.
    3. Saponara M, Ambrosini V, Nannini M, Gatto L, Astolfi A, Urbini M, Indio V, Fanti S, Pantaleo MA. (18)F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. Ther Adv Med Oncol. 2018 Aug 30;10:1758835918793569.
    4. Ravegnini G, Urbini M, Simeon V, Genovese C, Astolfi A, Nannini M, Gatto L, Saponara M, Ianni M, Indio V, Brandi G, Trino S, Hrelia P, Biasco G, Angelini S, Pantaleo MA. An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenomics J. 2018 Sep 20. [Epub ahead of print]
    5. Urbini M, Nannini M, Astolfi A, Indio V, Vicennati V, De Luca M, Tarantino G, Corso F, Saponara M, Gatto L, Santini D, Di Dalmazi G, Pagotto U, Pasquali R, Pession A, Biasco G, Pantaleo MA. Whole Exome Sequencing Uncovers Germline Variants of Cancer-Related Genes in Sporadic Pheochromocytoma. Int J Genomics. 2018:6582014
    6. Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, D'Ambrosio L, Incorvaia L, Stellato M, Spalato Ceruso M, Napolitano A, Valeri S, Santini D, Tonini G, Casali PG, Dei Tos AP, Pantaleo MA. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. Ther Adv Med Oncol. 2018 Aug 29;10:1758835918794623.
    7. Nannnini M, Dondi G, Santini D, De Leo A, Dei Tos AP, Zamagni C, Saponara M, Gatto L, Nigro C, Bertaccini P, Zompatori M, De Iaco P, Perrone AM, Pantaleo MA. A single-center experience on the management of adenosarcoma: a successful report of an integrated medical and surgical approach. Clinical Medicine Insights: Oncology 2018. 2018 Jun 18;12:1179554918782477.
    8. Urbini M, Indio V, Astolfi A, Tarantino G, Renne SL, Pilotti S, Dei Tos AP, Maestro R, Collini P, Nannini M, Saponara M, Murrone L, Dagrada GP, Colombo C, Gronchi A, Pession A, Casali PG, Stacchiotti S, Pantaleo MA. Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. Int J Mol Sci. 2018 Jun 23;19(7)
    9. De Leo A, Nannini M, Dondi G, Santini D, Urbini M, Gruppioni E, De Iaco P, Perrone AM, Pantaleo MA. Unusual bilateral ovarian metastases from ileal gastrointestinal stromal tumor (GIST): a case report. BMC Cancer. 2018 Mar 16;18(1):301
    10. Indio V, Astolfi A, Tarantino G, Urbini M, Patterson J, Nannini M, Saponara M, Gatto L, Santini D, do Valle IF, Castellani G, Remondini D, Fiorentino M, von Mehren M, Brandi G, Biasco G, Heinrich MC, Pantaleo MA. Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. Int J Mol Sci. 2018 Mar 4;19(3)
    11. Gatto L, Facchini G, Saponara M, Nannini M, Rossi G, Di Scioscio V, Biasco G, Pantaleo MA. Successful selective arterial embolizations for bone metastases in renal cell carcinoma integrated with systemic therapies: A case report. Radiol Case Rep. 2017 Aug 16;12(4):775-779.

    2017

    1. Urbini M, Astolfi A, Indio V, Tarantino G, Serravalle S, Saponara M, Nannini M, Gronchi A, Fiore M, Maestro R, Brenca M, Dei Tos AP, Dagrada GP, Negri T, Pilotti S, Casali PG, Biasco G, Pession A, Stacchiotti S, Pantaleo MA. Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. Oncotarget. 2017 May 17;8(36):60036-60045
    2. Mandrioli M, Mastrangelo L, Masetti M, Zanini N, Lega S, Nannini M, Gruppioni E, Altimari A, Dei Tos AP, Fabbri C, Jovine E. Characterization of malignant gastrointestinal stromal tumors-a single center experience. J Gastrointest Oncol 2017 Dec;8(6):1037-1045.
    3. Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA. Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Ther Adv Med Oncol 2017 Dec;9(12):731-739.
    4. Ravegnini G, Sammarini G, Nannini M, Pantaleo MA, Biasco G, Hrelia P, Angelini S. Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis. Autophagy. 2017 Mar 4;13(3):452-463
    5. Nannini M, Urbini M, Astolfi A, Biasco G, Pantaleo MA. The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST). J Transl Med. 2017 May 23;15(1):113
    6. De Simone B, Ansaloni L, Sartelli M, Coccolini F, Di Saverio S, Pantaleo MA, Saponara M, Nannini M, Abongwa HK, Napoli JA, Catena F. What is changing in the surgical treatment of gastrointestinal stromal tumors after multidisciplinary approach? A comprehensive literature's review. Minerva Chir. 2017 Feb 14
    7. Ravegnini G, Nannini M, Zenesini C, Simeon V, Sammarini G, Urbini M, Gatto L, Saponara M, Biasco G, Pantaleo MA, Venturoli N, Hrelia P, Angelini S. An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. Angiogenesis. 2017 Feb;20(1):139-148.
    8. Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, Tarantino G, Angelini S, Gronchi A, Vincenzi B, Grignani G, Colombo C, Fumagalli E, Gatto L, Saponara M, Ianni M, Paterini P, Santini D, Pirini MG, Ceccarelli C, Altimari A, Gruppioni E, Renne SL, Collini P, Stacchiotti S, Brandi G, Casali PG, Pinna AD, Astolfi A, Biasco G. Genome-wide Analyses Identifies MEN1 and MAX Mutation and a Neuroendocrine-like Molecular Heterogeneity in Quadruple WT GIST. Mol Cancer Res. 2017 May;15(5):553-562
    9. Gatto L, Nannini M, Saponara M, Di Scioscio V, Beltramo G, Frezza GP, Ercolani G, Pinna AD, Astolfi A, Urbini M, Brandi G, Biasco G, Pantaleo MA. Radiotherapy in the management of gist: state of the art and new potential scenarios. Clin Sarcoma Res. 2017 Jan 10;7:1.

    2016

    1. Pantaleo MA, Ravegnini G, Astolfi A, Simeon V, Nannini M, Saponara M, Urbini M, Gatto L, Indio V, Sammarini G, Santini D, Ferracin M, Negrini M, Hrelia P, Biasco G, Angelini S. Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors. Epigenomics 2016 Oct;8(10):1347-1366
    2. Ravegnini G, Nannini M, Simeon V, Musti M, Sammarini G, Saponara M, Gatto L, Urbini M, Astolfi A, Biasco G, Pantaleo MA, Venturoli N, Hrelia P, Angelini S. Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. Tumour Biol 2016;37(10):13413-13423.
    3. Pantaleo MA, Nannini M. Long-term outcome of molecular subgroups of gastrointestinal stromal tumour patients treated with standard-dose imatinib in the BFR14 trial: The wild-type gastrointestinal stromal tumours are not a single group yet. Eur J Cancer. 2016 Feb 28;58:38-40.
    4. Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall'Olio FG, Barbera MA, Pantaleo MA, Biasco G. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World J Gastroenterol. 2016 Jan 14;22(2):519-33.
    5. Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, Spalato Ceruso M, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos AP, Casali P, Tonini G. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget. 2016 Oct 25;7(43):69412-69419

    2015

    1. Saponara M, Urbini M, Astolfi A, Indio V, Ercolani G, Del Gaudio M, Santini D, Pirini MG, Fiorentino M, Nannini M, Lolli C, Mandrioli A, Gatto L, Brandi G, Biasco G, Pinna AD, Pantaleo MA. Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS). Oncotarget. 2015 Dec 8;6(39):42243-57.
    2. Astolfi A, Urbini M, Indio V, Nannini M, Genovese CG, Santini D, Saponara M, Mandrioli A, Ercolani G, Brandi G, Biasco G, Pantaleo MA. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). BMC Genomics. 2015 Nov 3;16:892.
    3. Nannini M, Ravegnini G, Angelini S, Astolfi A, Biasco G, Pantaleo MA. miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers. Epigenomics. 2015 Sep;7(6):1033-49.
    4. Urbini M, Astolfi A, Indio V, Heinrich MC, Corless CL, Nannini M, Ravegnini G, Biasco G, Pantaleo MA. SDHC methylation in gastrointestinal stromal tumors (GIST): a case report. BMC Med Genet. 2015 Sep 28;16:87.
    5. Minichillo S, Pantaleo MA, Nannini M, Coccolo F, Gatto L, Biasco G, Brandi G. Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma. BMC Res Notes. 2015 Jul 30;8:325.
    6. Ravegnini G, Nannini M, Sammarini G, Astolfi A, Biasco G, Pantaleo MA, Hrelia P, Angelini S. Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis. Int J Mol Sci. 2015 Jul 9;16(7):15592-608.
    7. Nannini M, Biasco G, Pantaleo MA; The GIST Study Group, Bologna. An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild type gastrointestinal stromal tumours - Letter to the editor. Histopathology. 2015 Nov;67(5):746-7
    8. Pantaleo MA, Lolli C, Nannini M, Astolfi A, Indio V, Saponara M, Urbini M, La Rovere S, Gill A, Goldstein D, Ceccarelli C, Santini D, Rossi G, Fiorentino M, Di Scioscio V, Fusaroli P, Mandrioli A, Gatto L, Catena F, Basso U, Ercolani G, Pinna AD, Biasco G. Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. Genet Med. 2015 May;17(5):391-5.
    9. Pantaleo MA, Nannini M, Corless CL, Heinrich MC. Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. Cancer Med. 2015 Jan;4(1):101-3.

    2014

    1. Saponara M, Pantaleo MA, Nannini M, Biasco G. Treatments for gastrointestinal stromal tumors that are resistant to standard therapies. Future Oncol. 2014 Oct;10(13):2045-59.
    2. Nannini M, Astolfi A, Urbini M, Indio V, Santini D, Heinrich MC, Corless CL, Ceccarelli C, Saponara M, Mandrioli A, Lolli C, Ercolani G, Brandi G, Biasco G, Pantaleo MA. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer 2014;14:685.
    3. Angelini S, Ravegnini G, Nannini M, Bermejo JL, Musti M, Pantaleo MA, Fumagalli E, Venturoli N, Palassini E, Consolini N, Casali PG, Biasco G, Hrelia P. Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. Eur J Hum Genet. 2015 Jun;23(6):817-23.
    4. Saponara M, Lolli C, Nannini M, DI Scioscio V, Serra C, Mandrioli A, Pallotti MC, Biasco G, Pantaleo MA. Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. Oncol Lett 2014;8(4):1793-1799.
    5. Pantaleo MA, Astolfi A, Urbini M, Fuligni F, Saponara M, Nannini M, Lolli C, Indio V, Santini D, Ercolani G, Brandi G, Pinna AD, Biasco G. Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors. Clin Sarcoma Res. 2014;4:9.
    6. Nannini M, Astolfi A, Urbini M, Biasco G, Pantaleo MA. Liquid biopsy in gastrointestinal stromal tumors: a novel approach. J Transl Med. 2014;12:210.
    7. Pallotti MC, Nannini M, Agostinelli C, Leoni S, Scioscio VD, Mandrioli A, Lolli C, Saponara M, Pileri S, Bolondi L, Biasco G, Pantaleo MA. Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. World J Gastroenterol. 2014 Jun 14;20(22):7049-54.
    8. Pantaleo MA, Nannini M, Astolfi A, Biasco G. Novel Clinically Relevant Genes in GIST--Letter. Clin Cancer Res. 2014 Apr 1;20(7):2014
    9. Nannini M, Biasco G, Astolfi A, Urbini M, Pantaleo MA. Insulin-like Growth Factor (IGF) system and gastrointestinal stromal tumours (GIST): present and future. Histol Histopathol. 2014 Feb;29(2):167-75
    10. Pantaleo MA, Astolfi A, Urbini M, Nannini M, Paterini P, Indio V, Saponara M, Formica S, Ceccarelli C, Casadio R, Rossi G, Bertolini F, Santini D, Pirini MG, Fiorentino M, Basso U, Biasco G. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST. Eur J Hum 2014 Jan;22(1):32-9

    2013

    1. Nannini M, Astolfi A, Biasco G, Pantaleo MA. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). J Med Genetics 2013 Oct;50(10):653-61
    2. Nannini M, Pantaleo MA, Biasco G. Role of molecular analysis in the adjuvant treatment of gastrointestinal stromal tumours: it is time to define it. World J Gastroenterol. 2013;19:2583-6.
    3. Nannini M, Astolfi A, Paterini P, Urbini M, Santini D, Catena F, Indio V, Casadio R, Pinna AD, Biasco G, Pantaleo MA. Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction. Future Oncol. 2013 Jan;9(1):121-6.

    2012

    1. Pallotti MC, Pantaleo MA, Nannini M, Centofanti F, Fabbrizio B, Montanari M, Baraldi O, Saponara M, Lolli C, Mandrioli A, Biasco G, Prandini R. Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. Case Rep Oncol 2012;5(3):651-6.
    2. Catena F, Di Battista M, Ansaloni L, Pantaleo M, Fusaroli P, Di Scioscio V, Santini D, Nannini M, Saponara M, Ponti G, Persiani R, Delrio P, Coccolini F, Di Saverio S, Biasco G, Lazzareschi D, Pinna A. Microscopic margins of resection influence primary gastrointestinal stromal tumor survival. Onkologie. 2012;35(11):645-8.
    3. Angelini S, Pantaleo MA, Ravegnini G, Zenesini C, Cavrini G, Nannini M, Fumagalli E, Palassini E, Saponara M, Di Battista M, Casali PG, Hrelia P, Cantelli-Forti G, Biasco G. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol Res. 2012 Nov 2;68(1):1-6.
    4. Nannini M, Pantaleo MA, Catena F, Romano S, Tondo S, Pirini MG, Lolli C, Maleddu A, Mandrioli A, Gatto L, Saponara M, Pallotti MC, Dei Tos AP, Pinna AD, Biasco G. Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. Int J Surg Case Rep. 2012 Sep 19;4(1):7-10.
    5. Nannini M, Pantaleo MA, Maleddu A, Saponara M, Mandrioli A, Lolli C, Pallotti MC, Gatto L, Santini D, Paterini P, DI Scioscio V, Catena F, Fusaroli P, Pinna AD, Tos AP, Biasco G. Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours. Oncol Lett. 2012;3:677-681.
    6. Pantaleo MA, Mandrioli A, Saponara M, Nannini M, Erente G, Lolli C, Biasco G. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012 Jun 11;12:231.
    7. Saponara M, Pantaleo MA, Nannini M, Biasco G. Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice. Target Oncol. 2012 Dec;7(4):243-6
    8. Pantaleo MA, Nannini M, Saponara M, Gnocchi C, Di Scioscio V, Lolli C, Catena F, Astolfi A, Di Battista M, Biasco G; GIST Study Group, University of Bologna, Bologna, Italy. Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumours. Anticancer Drugs. 2012 Jun;23(5):567-72
    9. Nannini M, Biasco G, Pallotti MC, Di Battista M, Santini D, Paterini P, Maleddu A, Mandrioli A, Lolli C, Saponara M, Di Scioscio V, Zompatori M, Catena F, Fusaroli P, Dei Tos AP, Pantaleo MA. Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. Med Oncol. 2012 Mar;29(1):144-50.

    2011

    1. Lolli C, Pantaleo MA, Nannini M, Saponara M, Pallotti MC, Scioscio VD, Barbieri E, Mandrioli A, Biasco G. Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. Rare Tumors 2011;3:e49.
    2. Pantaleo MA, Astolfi A, Nannini M, Ceccarelli C, Formica S, Santini D, Heinrich MC, Corless C, Dei Tos AP, Paterini P, Catena F, Maleddu A, Saponara M, Di Battista M, Biasco G. Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours. Histopathology 201159:1071-80.
    3. Pantaleo MA, Nannini M, Astolfi A, Biasco G; GIST Study Group Bologna. A distinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations. Am J Surg Pathol 2011;35:1750-2
    4. Nannini M, Biasco G, Maleddu A, Pantaleo MA. New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors (GISTs): present and future. Expert Opin Ther Targets. 2011 Jul;15(7):803-15.
    5. Nannini M, Pantaleo MA, Biasco G. The follow-up after radical surgery of colorectal cancer: is it time for a “tailored” strategy? Clin Colorectal Cancer 2011 Jun;10(2):81-4
    6. Di Scioscio V, Greco L, Pallotti MC, Pantaleo MA, Maleddu A, Nannini M, Bazzocchi A, Di Battista M, Mandrioli A, Lolli C, Saponara M, Giorgio G, Biasco G, Zompatori M. Three cases of bone metastases in patients with gastrointestinal stromal tumors. Rare Tumors. 2011 Apr 4;3(2):e17.
    7. Maleddu A, Pantaleo MA, Nannini M, Biasco G. The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting. J Transl Med. 2011 May 23;9:75.
    8. Nannini M, Biasco G, Di Scioscio V, Di Battista M, Zompatori M, Catena F, Castellucci P, Paterini P, Dei Tos AP, Stella F, Maleddu A, Pantaleo MA. Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors (case reports). Oncol Rep. 2011 Jan;25(1):113-20.
    9. Nannini M, Pantaleo MA, Paterini P, Piazzi G, Ceccarelli C, La Rovere S, Maleddu A, Biasco G. Molecular detection of epidermal growth factor receptor (EGFr) in colorectal cancer: does it still make sense? Colorectal Dis. 2011 May;13(5):542-8

    2010

    1. Pantaleo MA, Nicoletti G, Nanni C, Gnocchi C, Landuzzi L, Quarta C, Boschi S, Nannini M, Di Battista M, Castellucci P, Fanti S, Lollini PL, Bellan E, Castelli M, Rubello D, Biasco G. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. J Exp Clin Cancer Res. 2010 Dec 30;29:173
    2. Pantaleo MA, Nannini M, Di Battista M, Catena F, Biasco G. Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy. Cancer Treat Rev. 2010 Feb;36(1):63-8.
    3. Pantaleo MA, Astolfi A, Nannini M, Biasco G. The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs). J Transl Med. 2010 Nov 15;8:117.
    4. Astolfi A, Nannini M, Pantaleo MA, Di Battista M, Heinrich MC, Santini D, Catena F, Corless CL, Maleddu A, Saponara M, Lolli C, Di Scioscio V, Formica S, Biasco G. A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest. 2010 Sep;90(9):1285-94.
    5. Pantaleo MA, Di Battista M, La Rovere S, Astorino M, Catena F, Lolli C, Saponara M, Maleddu A, Nannini M, Di Scioscio V, Santini D, Ceccarelli C, Paterini P, Castellucci P, Astolfi A, Mandrioli A, Fusaroli P, Tomassetti P, Pinna AD, Biasco G. Management of patients with gastrointestinal stromal tumor in clinical practice in Italy: a critical "event tree model" analysis of decision-making processes and outcomes. Tumori. 2010 Mar-Apr;96(2):219-28

    2009

    1. Di Cicilia R, Castellucci P, Nannini M, Balbi T, Zannetti G, Fanti S, Biasco G, Pantaleo MA. Unusual finding of benign Abrikossoff tumor by F-18 FDG-PET mimicking melanoma recurrence. Clin Nucl Med. 2009 Oct;34(10):696-7.
    2. Maleddu A, Pantaleo MA, Castellucci P, Astorino M, Nanni C, Nannini M, Busato F, Di Battista M, Farsad M, Lodi F, Boschi S, Fanti S, Biasco G. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori. 2009 May-Jun;95(3):382-4.
    3. Pantaleo MA, Astolfi A, Di Battista M, Heinrich MC, Paterini P, Scotlandi K, Santini D, Catena F, Manara MC, Nannini M, Maleddu A, Saponara M, Lolli C, Formica S, Biasco G. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer. 2009 Dec 15;125(12):2991-4.
    4. Pantaleo MA, Nannini M, Fanti S, Boschi S, Lollini PL, Biasco G. Molecular imaging of EGFR: it's time to go beyond receptor expression. J Nucl Med. 2009 Jul;50(7):1195-6; author reply 1196, 1197.
    5. Maleddu A, Pantaleo MA, Nannini M, Di Battista M, Saponara M, Lolli C, Biasco G. Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). Oncol Rep. 2009 Jun;21(6):1359-66.
    6. Nannini M, Pantaleo MA, Maleddu A, Al-Nahhas A, Rubello D, Fanti S, Biasco G. The Response Evaluation Criteria in Solid Tumors: until when? Nucl Med Commun. 2009 Mar;30(3):185-7.
    7. Nannini M, Nobili E, Di Cicilia R, Brandi G, Maleddu A, Pantaleo MA, Biasco G. To widen the setting of cancer patients who could benefit from metronomic capecitabine. Cancer Chemother Pharmacol. 2009 Jun;64(1):189-93.
    8. Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev. 2009 May;35(3):201-9.
    9. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Nanni C, Boschi S, Lodi F, Nicoletti G, Landuzzi L, Lollini PL, Biasco G. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann Oncol. 2009 Feb;20(2):213-26.

    2008

    1. Pantaleo MA, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G, Brandi G, Martinelli G, Pession A, Pinna AD, Biasco G. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer. 2008 Nov 18;99(10):1729-34.
    2. Brandi G, Nannini M, Pantaleo MA, Fanello S, Farsad M, Fanti S, Ercolani G, Maleddu A, Di Battista M, Biasco G. Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. Chemotherapy. 2008;54(6):421-4.
    3. Pantaleo MA, Nannini M, Lopci E, Castellucci P, Maleddu A, Lodi F, Nanni C, Allegri V, Astorino M, Brandi G, Di Battista M, Boschi S, Fanti S, Biasco G. Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases. Int J Oncol. 2008 Sep;33(3):443-52.
    4. Pantaleo MA, Fanti S, Nannini M, Boschi S, Nanni C, Maleddu A, Rubello D, Biasco G. What oncologists need and require from nuclear medicine. Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1761-5.
    5. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Ambrosini V, Nanni C, Boschi S, Biasco G. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev. 2008 Apr;34(2):103-21.

    2007

    1. Pantaleo MA, Saponara M, Nannini M, Biasco G. Targeted therapies in solid tumours: results and promises. Minerva Med. 2007 Oct;98(5):603-23. Review.

     

Latest news

At the moment no news are available.

RSS